Sukhodolia S. A., Moroz V. A.

INTRAOPERATIVE MULTIPLE BIOPSY OF PANCREATIC TISSUE AS A MORE EFFECTIVE METHOD OF DIAGNOSIS

---

Show/Download

About the author:

Sukhodolia S. A., Moroz V. A.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

Our study demonstrates that the success and advantage of early detection of pancreatic cancer (PaC) provides better treatment effects, improved quality of life, and positive long-term outcomes after surgery. The goal of the pancreatic ductal adenocarcinoma screening program is to detect and treat T1N0M0 or high-grade dysplasia (pancreatic intraepithelial neoplasia (PanIN), mucinous cystic neoplasia (MCN), intraductal papillary mucinous neoplasia (IPMN), as precursors to the pancreatic cancer (PaC). It is also known that differentiation between PaC and chronic pancreatitis (CP) is difficult and unreliable when performing CT, MRI, and MRCP. Unfortunately, there is currently no recommended combination of biomarkers approved for the diagnosis and prognosis of PaC. It is well known that recurrent acute pancreatitis (AP) leads to CP, which is a well-known risk factor for the development of PaC. Over the past decade, numerous studies have evaluated AP as a risk factor for the development of PaC. That is why we developed and implemented the technique of intraoperative multiple biopsy in patients with neglected and complicated CP, for which a certificate of copyright registration was obtained «Intraoperative multiple biopsy technique of the pancreas» №114856 from 19.09.2022. During 2016-2023, the study included 55 patients which we operated on, with complicated CP, where this technique was used. The method is simple and accessible, and the results obtained were the reason for changing the surgical correction of complicated CP in the direction of increasing the resection volume, which ensured and guaranteed more radical and high-quality treatment with improved quality of life in the immediate and long-term postoperative period.

Tags:

Bibliography:

1. Zhao Q, Xie H, Wang X, Xie J, Liu J, Bai Y, et al. Comprehensive bioinformatics analysis of the prognostic value and immune infiltration of CAPN2 in pancreatic adenocarcinoma. Gene. 2024;934:149035. DOI: 10.1016/j.gene.2024.149035.
2. Dai Y, Guan X, Guo F, Kong X, Ji S, Shang D, et al. Botanical drugs and their natural compounfs: a neglected treasury for inhibiting the carcinogenesis of pancreatic ductal adenocarcinoma. Pharmaceutical Biology. 2024;62(1):853-73. DOI: https://doi.org/10.1080/1388020 9.2024.2421759.
3. Waleleng BJ, Adiwinata R, Wenas NT, Haroen H, Rotty L, Gosal F, et al. Screening of pancreatic cancer: Target population, optimal timing and how? Ann Med Surg (Lond). 2022;84:104814. DOI: 10.1016/j.amsu.2022.104814.
4. Koopmann BDM, Omidvari AH, Lansdorp-Vogelaar I, Cahen DL, Bruno MJ, de Kok IMCM. The impact of pancreatic cancer screening on life expectancy: A systematic review of modeling studies. Int J Cancer. 2023;152(8):1570-1580. DOI: 10.1002/ijc.34379.
5. Draus T, Ansari D, Andersson R. Model-based screening for pancreatic cancer in Sweden. Scandinavian Journal of Gastroenterology. 2022;58(5):534-541. DOI: https://doi.org/10.1080/00365521.2022.2142481.
6. Hasan S, Jacob R, Manne U, Paluri R. Advances in pancreatic cancer biomarkers. Oncol. Rev. 2019;13:69-76.
7. Kapszewicz M, Małecka-Wojciesko E. Simple serum pancreatic ductal adenocarcinoma (Pdac) protein biomarkers – Is there anything in sight? J. Clin. Med. 2021;10:5463.
8. Munigala S, Almaskeen S, Subramaniam DS, Bandi S, Bowe B, Xian H, et al. Acute Pancreatitis Recurrences Augment Long-Term Pancreatic Cancer Risk. Am. J. Gastroenterol. 2023;118:727-737.
9. Maisonneuve P, Lowenfels AB. Risk factors for pancreatic cancer: summary review of meta-analytical studies. Int J Epidemiol. 2015;44(1):186-98. DOI: 10.1093/ije/dyu240.
10. Hao L, Zeng XP, Xin L, Wang D, Pan J, Bi YW, et al. Incidence of and risk factors for pancreatic cancer in chronic pancreatitis: A cohort of 1656 patients. Dig Liver Dis. 2017;49(11):1249-56. DOI: 10.1016/j.dld.2017.07.001.
11. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes and Development. 2006;20(10):1218-49. DOI: 10.1101/gad.1415606.
12. Rooman I, Real FX. Pancreatic ductal adenocarcinoma and acinar cells: a matter of differentiation and development? Gut. 2012;61(3):449- 58. DOI: 10.1136/gut.2010.235804.
13. Sandgren EP, Quaife CJ, Paulovich AG, Palmiter RD, Brinster RL. Pancreatic tumor pathogenesis reflects the causative genetic lesion. Proc Nat Acad Sci USA. 1991;88(1):93-97.
14. Kirkegaard J, Mortensen FV, Cronin-Fenton D. Chronic Pancreatitis and Pancreatic Cancer Risk: A Systematic Review and Meta-analysis. Am J Gastroenterol. 2017;112(9):1366-72. DOI: 10.1038/ajg.2017.218.
15. Raksha NG, Halenova TI, Vovk TB, Sukhodolia SA, Beregova TV, Ostapchenko LI. Proteolitic imbalance as a key factor of the development of chronic pancreatitis with and without type 1 diabetes mellitus. Visnik problem biologii i medicine. 2019;3(152):186-191.
16. Synelʹnyk TB, Kravchenko OO, Kostyuk OS, Savchuk OM, Sukhodolya SA, Ostapchenko LI. Rozpodil serynovykh proteaz u plazmi krovi ta pidshlunkoviy zalozi za khronichnoho pankreatytu ta onkopatolohiyi Fiziologichnyi Zhurnal. 2022;68(6):31-43. [in Ukrainian].
17. Zhang ZH, Zhao DB, Zhao LI, Pan QJ, Shan Y, Wang CF, et al. The value of thin-layer cytology in intraoperative fine-needle aspiration biopsy of pancreatic cancer. Zhonghua Zhong Liu Za Zhi. 2008;30(6):476-9. 18.Zhao DB, Wang Y, Shan Y, Wang CF, Shao YF, Zhao P. Value of intraoperative fine-needle aspiration cytology and histopathologic biopsy in the diagnosis of pancreatic cancer. Zhonghua Zhong Liu Za Zhi. 2008;30(3):231-3.

Publication of the article:

«Bulletin of problems biology and medicine», 2024 Issue 4, 175, 469-476 pages, index UDC 616.37-002-007.253-089

DOI:

10.29254/2077-4214-2024-4-175-469-476